ibuprofen + phenylephrine hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ibuprofen + phenylephrine hydrochloride: clinical details
Prescribing considerations
- Confirm that both an NSAID and systemic decongestant are appropriate and that symptoms include congestion.
- Review cardiovascular, gastrointestinal, renal, hepatic and asthma risks, hydration and concurrent medicines.
- Older people are more susceptible to NSAID-associated gastrointestinal bleeding and perforation.
- The combination may mask fever and pain from infection; reassess persistent or worsening symptoms.
Contraindications and cautions
- Hypersensitivity to either ingredient, excipients, aspirin or another NSAID
- Previous NSAID-associated bronchospasm, rhinitis, angioedema or urticaria
- Active or recurrent peptic ulceration, gastrointestinal haemorrhage, or previous NSAID-related bleeding or perforation
- Hypertension, severe coronary or cardiovascular disease, severe heart, renal or hepatic failure
- Hyperthyroidism, phaeochromocytoma or prostatic enlargement
- Current or recent MAOI treatment
- Concurrent NSAID or COX-2 inhibitor use
- Third trimester of pregnancy
Monitoring
- Assess blood pressure and cardiovascular symptoms where risk factors or interacting medicines are present.
- Consider renal function and hydration in older, dehydrated or renally vulnerable patients and with ACE inhibitors, angiotensin-receptor blockers or diuretics.
- Watch for gastrointestinal bleeding, fluid retention, bronchospasm, severe skin reactions and persistent infection symptoms.
Clinical pharmacology
Ibuprofen is a propionic-acid NSAID that inhibits prostaglandin synthesis and reversibly inhibits platelet aggregation. Phenylephrine is a postsynaptic alpha-receptor agonist that reduces nasal mucosal oedema through vasoconstriction; oral bioavailability is limited by first-pass metabolism.
Formulation and product differences
- The selected preparation is a yellow film-coated oral tablet marked with an identifying motif.
- It contains Sunset Yellow E110, which may cause allergic reactions.
- The formulation is described as essentially sodium-free.
ibuprofen + phenylephrine hydrochloride preparations and strengths
Tablet
Route: Oral
Strengths: 200 mg + 5 mg
ibuprofen + phenylephrine hydrochloride interactions
Check for interactions and duplicate ingredients, especially with cardiovascular, psychiatric or anticoagulant treatment.
MAO inhibitors
Contraindicated during treatment and for two weeks after stopping because phenylephrine may cause a dangerous rise in blood pressure.
Other NSAIDs, including naproxen and COX-2 inhibitors
Combining them increases gastrointestinal, kidney and other NSAID-related adverse effects.
Aspirin
Adverse effects may increase, and regular ibuprofen use may interfere with aspirin's antiplatelet action.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.